

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Faricimab for treating wet age-related macular degeneration

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

A stakeholder commented that visual impairment resulting from wet age-related macular degeneration is recognised as a disability. So, the patient population of this appraisal is a protected group under the Equality Act of 2010.

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

The committee will take into account that faricimab would be used in people with visual impairment when formulating its recommendations.
--

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No.

- | |
|--|
| 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made? |
|--|

No additional stakeholders related to potential equality issues were identified during the scoping process.

Approved by Associate Director (name): Ross Dent

Date: 15/09/2021